A new study being presented at #AACR26 highlights a novel neoadjuvant therapy approach for clear cell renal cell carcinoma, demonstrating highly promising efficacy in a small, single-arm phase 1 trial.

This strategy combines immunotherapy targeting both T cells (anti-PD-1) and